Valuation: Avidity Biosciences, Inc.

Market Cap 11.3B 10.24B 9.47B 8.54B 16.1B 1,065B 16.67B 114B 45.11B 569B 42.4B 41.5B 1,806B P/E 2024
-10.1x
P/E 2025 -14.5x
Enterprise Value 9.65B 8.75B 8.09B 7.3B 13.75B 910B 14.24B 97.17B 38.53B 486B 36.21B 35.45B 1,543B EV / Sales 2024
181x
EV / Sales 2025 492x
Free-Float
10.55%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Avidity Biosciences, Inc.

1 day+0.03%
Current year+0.96%
Current year 72
Extreme 72
73.06
1 year 70.42
Extreme 70.42
73.06
3 years 5.68
Extreme 5.68
73.06
5 years 4.82
Extreme 4.825
73.06
10 years 4.82
Extreme 4.825
73.06
Manager TitleAgeSince
President - 26/02/2026
Treasurer - 26/02/2026
Corporate Secretary - 26/02/2026
Director TitleAgeSince
Director/Board Member - 26/02/2026
Director/Board Member - 26/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
27/02/26 Issuer sale

Director

110,073 0.0766%
27/02/26 Issuer sale

Chief Technology Officer

547,865 0.3814%
27/02/26 Issuer sale

General Counsel

302,054 0.2103%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+2.85%+1,068.86% 11.3B
+1.26%+6.61%+40.79%+145.27% 1,286B
+0.79%+3.45%+45.84%+92.04% 688B
+0.20%+1.28%+26.97%+114.41% 521B
-0.44%+3.69%+41.45%+70.04% 386B
+0.55%+0.70%+59.02%+45.79% 364B
-0.12%+0.74%+28.39%+60.32% 302B
+0.37%+0.37%+3.33%+38.57% 287B
-0.30%+1.14%+38.29%+70.56% 252B
+0.08%+0.71%+34.44%+123.99% 208B
Average +0.24%+1.87%+32.14%+182.98% 431B
Weighted average by Cap. +0.54%+3.25%+37.61%+101.83%

Financials

2024 2025
Net sales 10.9M 9.87M 9.13M 8.24M 15.53M 1.03B 16.08M 110M 43.51M 549M 40.89M 40.03M 1.74B 18.76M 17M 15.72M 14.18M 26.73M 1.77B 27.67M 189M 74.88M 945M 70.38M 68.89M 3B
Net income -322M -292M -270M -244M -459M -30.39B -476M -3.25B -1.29B -16.23B -1.21B -1.18B -51.53B -685M -620M -574M -518M -976M -64.55B -1.01B -6.89B -2.73B -34.48B -2.57B -2.51B -109B
Net Debt -1.49B -1.35B -1.25B -1.13B -2.13B -141B -2.21B -15.05B -5.97B -75.28B -5.61B -5.49B -239B -1.65B -1.49B -1.38B -1.25B -2.35B -155B -2.43B -16.59B -6.58B -82.99B -6.18B -6.05B -263B
Projected Income Statement - Annual - Avidity Biosciences, Inc.
Logo Avidity Biosciences, Inc.
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Avidity Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. RNAM Stock